Business
Kali Extracts Presents Cannabis Extract Biopharmaceutical Strategy Targeting $170 Million Pharmaceutical Market Opportunity
Kali Extracts Presents Cannabis Extract Biopharmaceutical Strategy Targeting $170 Million Pharmaceutical Market Opportunity.
About this update from Kali Inc
[{"type":"text","content":"\nDALLAS, April 17, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today published a presentation elaborating on the company’s overall strategy to discover, develop and commercialize novel therapeutics from its proprietary cannabinoid product platform.  KALY owns and operates a patented cannabis extraction process. Following four years of research and development, the company recently executed a strategy to bring the resulting intellectual property (IP) into a public company as part of a plan to capitalize its next stage of development.  KALY is that public company platform.  In conjunction with that plan, the company has recently disclosed four of its leading research and development initiatives targeting four specific health issues: \n Chronic Obstructive Pulmonary Disease (COPD) - The market for COPD treatment is anticipated to reach $14 billion by 2025;  Type 2 Diabetes - The market for Type 2 Diabetes is expected to be a $64 billion market by 2026; Cancer Pain Management - The overall pain management treatment market is anticipated to reach $83 billion by 2024, and  Epilepsy - The market for epilepsy treatment is anticipated to reach $9 billion by 2022. The presentation below and incorporated into the company’s website offers further detail on the company’s progress to date and plans moving forward to commercialize cannabis therapies. Patented Cannabis Extracts Targeting $170 Million Pharmaceutical Treatments In the fourth quarter of last year, 2018, KALY acquired NCM Biotech (NCMB).  NCMB is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from a proprietary cannabinoid product platform in a broad range of disease areas.  In four years of operations, the company has established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drug discovery and patented development process.  The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity.  KALY, through its subsidiary, NCMB has a deep pipeline of additional cannabinoid product candidates including four distinct compounds.  KALY has...